Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

VG801

PreclinicalSmall molecule

VVeonGen Therapeutics GmbH

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinal Dystrophy Due to Biallelic ABCA4 MutationsRecruiting

Retinal Dystrophy Due to Biallelic ABCA4 MutationsPreclinical

Recruiting

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Retinal Dystrophy Due to Biallelic ABCA4 Mutations

NCT07002398

Clinical

Trials by Indication[1]

Retinal Dystrophy Due to Biallelic ABCA4 Mutations1 trial

A Single Arm, Ph1/2, Open-label, Multicenter Trial With Dose-exploration Via Subretinal Injection to Evaluate the Safety and Preliminary Efficacy of VG801 for Treatment of ABCA4 Mutation-associated Recessive Hereditary Retinal Dystrophy (Stargardt Disease)

Recruiting·VVeonGen Therapeutics GmbH·Preclinical·NCT07002398·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VG801. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VG801 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VG801. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — VeonGen Therapeutics GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: VVeonGen Therapeutics GmbH

Related News